Table 1.

EC₂₅ values for adenosine-induced inhibitory effects before and after different pharmacological treatments

	Proximal colon			Distal colon
	EC25 (mM)	95% CLs (mM)	n	EC25 95% (mM)	CLs (mM)	n
Control	0.044	0.038–0.050	4	0.040	0.035–0.044	4
PPADS	0.058	0.048–0.072	4	0.043	0.036–0.052	4
Control	0.045	0.031–0.068	5	0.043	0.031–0.060	5
DPCPX	0.336*	0.256–0.440	5	0.069*	0.039–0.120	5
Control	0.040	0.033–0.070	6	0.045	0.031–0.075	6
DMPX	0.051	0.034–0.075	6	0.920*	0.650–1.297	6
Control	—	—		0.042	0.026–0.098	4
DPCPX+DMPX	—	—		3.365§	2.786–4.055	4
Control	—	—		0.046	0.028–0.074	5
CSC	—	—		0.059	0.027–0.130	5
Control	—	—		0.044	0.030–0.071	5
MRS 1754	—	—		0.596*	0.354–0.881	5
Control	0.041	0.031–0.075	4	0.043	0.030–0.077	4
MRS 1220	0.046	0.034–0.064	4	0.051	0.032–0.079	4
Control	0.035	0.027–0.046	6	0.042	0.031–0.076	6
TTX	0.049	0.027–0.090	6	0.780*	0.052–1.112	6
Control	—	—		0.050	0.032–0.089	4
DPCPX	—	—		0.084*	0.047–0.150	4
DPCPX+TTX	—	—		1.343§	0.960–1.875	4
Control	—	—		0.051	0.029–0.108	5
MRS 1754	—	—		0.483*	0.260–0.898	5
MRS 1754+TTX	—	—		0.583*	0.335–1.106	5
Control	0.049	0.030–0.078	6	0.044	0.029–0.066	6
L-NAME	0.067	0.040–0.111	6	0.710*	0.590–0.850	6
Control	—	—		0.034	0.024–0.048	4
DPCPX	—	—		0.073*	0.034–0.156	4
DPCPX+L-NAME	—	—		1.076§	0.863–1.346	4
Control	—	—		0.047	0.026–0.085	4
MRS 1754	—			0.454*	0.221–0.665	4
MRS 1754+L-NAME	—	—		0.501*	0.356–0.704	4
Control	—	—		0.044	0.027–0.075	4
ODQ	—	—		0.530*	0.480–0.620	4

^*P<0.05 when compared to the respective control.

^§P<0.05 when compared to DPCPX alone.